DPP4 and Alzheimer disease: In turn, long-term dipeptidyl peptidase IV inhibition by sitagliptin was shown to increase cerebral GLP-1 levels and reduce βAPP and Aβ accumulation, as well as neuroinflammation, in AD-prone rats [112].